Stock Price & Analysis

The S1 support level for ELVN Stock is $19.14 ,The R1 resistant level for ELVN Stock is $21.96.

As of the end of day on 2025-03-13, the price of ELVN Stock was $20.58.

The target price for ELVN Stock according to analyst rating is 38.75, with the highest price target at 42.00 and the lowest at 36.00. Analysts have a Strong Buy rating on ELVN Stock overall.

The market cap of ELVN is $1.0B.

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.

ELVN has a total of 46 employees.